1
NUR 521 Advanced Pharmacology EXAM 3
PRACTICE QUESTIONS AND ANSWERS WITH
RATIONALES 2025-2026 University of Alabama.
Domain 1: Antimicrobials, Beta-Lactams & Antivirals (14 Questions)
1. A 68-year-old male is admitted with bacteremia secondary to an infected diabetic foot
ulcer. Culture results confirm methicillin-resistant Staphylococcus aureus (MRSA). The
prescriber initiates Vancomycin. What is the specific mechanism of action that allows
Vancomycin to treat this resistant organism?
A. It inhibits the synthesis of the bacterial cell wall by binding to the 30S ribosomal subunit.
B. It binds to the D-alanyl-D-alanine terminal of the peptidoglycan precursor, preventing
cross-linking and transpeptidation.
C. It disrupts the cytoplasmic membrane potential, leading to rapid cell death.
D. It inhibits DNA gyrase, preventing bacterial DNA replication.
[CORRECT] B. It binds to the D-alanyl-D-alanine terminal of the peptidoglycan precursor,
preventing cross-linking and transpeptidation.
Rationale: Vancomycin is a glycopeptide antibiotic that exerts its bactericidal effect by binding
tightly to the D-alanyl-D-alanine terminus of the cell wall precursor pentapeptide. This
binding physically blocks the transglycosylation and transpeptidation (cross-linking) reactions
essential for cell wall rigidity. Unlike beta-lactams, which bind penicillin-binding proteins
(PBPs), Vancomycin binds the substrate itself, making it effective against MRSA strains that
have altered PBPs.
2. A patient with MRSA is being treated with Vancomycin. The nurse practitioner is
monitoring for nephrotoxicity. Which specific laboratory value must be monitored closely to
ensure safe therapeutic levels while minimizing toxicity?
A. Serum Prothrombin Time (PT)
, 2
B. Serum Creatinine and Vancomycin trough levels
C. Platelet count
D. Aspartate Aminotransferase (AST)
[CORRECT] B. Serum Creatinine and Vancomycin trough levels
Rationale: Vancomycin is associated with nephrotoxicity, particularly when trough levels are
consistently elevated (generally >15-20 mcg/mL). Monitoring serum creatinine allows for the
detection of acute renal injury, while monitoring random (or trough) levels ensures the drug
concentration is high enough to be effective (MIC ratio) but not so high as to cause kidney
damage.
3. A patient with a history of IV drug use presents with fever and a new heart murmur. Blood
cultures are pending, but there is a high clinical suspicion for MRSA endocarditis. The
prescriber orders Vancomycin. In addition to nephrotoxicity, what is another specific adverse
effect associated with the rapid infusion of Vancomycin?
A. Red Man Syndrome (histamine-mediated flushing and hypotension)
B. Stevens-Johnson Syndrome
C. Disulfiram-like reaction with alcohol
D. QT prolongation
[CORRECT] A. Red Man Syndrome (histamine-mediated flushing and hypotension)
Rationale: Red Man Syndrome is an infusion-related reaction characterized by flushing,
erythema, pruritus, and hypotension. It is caused by the direct, non-IgE-mediated release of
histamine from mast cells and basophils, typically occurring when Vancomycin is infused too
rapidly (e.g., over less than 60 minutes). It can be prevented or minimized by infusing the drug
over at least 60 to 120 minutes and pretreating with antihistamines.
, 3
4. Select all that apply: A patient is diagnosed with a severe MRSA infection. The healthcare
provider determines that Vancomycin therapy is appropriate. Which of the following are
critical monitoring parameters for this patient?
A. trough concentration drawn 30 minutes before the fourth dose
B. Serum creatinine and glomerular filtration rate (GFR)
C. Complete Blood Count (CBC) for eosinophilia
D. Ototoxicity assessment (hearing test)
E. Liver function tests (LFTs)
[CORRECT] A, B, C, D
Rationale:
A: Trough levels are drawn just before the next dose (steady state, usually prior to the 4th
dose) to ensure the minimum inhibitory concentration (MIC) is adequate.
B: Nephrotoxicity is a major risk, requiring renal function monitoring.
C: While less common than nephrotoxicity, Vancomycin can cause neutropenia or
eosinophilia.
D: Ototoxicity is a known, though less frequent, adverse effect of Vancomycin, particularly
with high trough levels or concurrent use of other ototoxic drugs (like aminoglycosides).
5. A 72-year-old female is admitted to the ICU with septic shock. Blood cultures grow
Escherichia coli that produces Extended-Spectrum Beta-Lactamase (ESBL). The initial empiric
therapy was Ceftriaxone. What is the specific pharmacologic rationale for de-escalating
therapy to a carbapenem (e.g., Meropenem)?
A. ESBL organisms hydrolyze the beta-lactam ring of penicillins and cephalosporins, rendering
them inactive.
B. ESBL organisms increase the efflux of Ceftriaxone out of the bacterial cell.
, 4
C. ESBL organisms alter the target binding site of Ceftriaxone.
D. Carbapenems are effective because they avoid the D-alanyl-D-alanine binding site.
[CORRECT] A. ESBL organisms hydrolyze the beta-lactam ring of penicillins and
cephalosporins, rendering them inactive.
Rationale: ESBLs are enzymes that confer resistance to penicillins, cephalosporins, and
aztreonam by hydrolyzing the beta-lactam ring. Carbapenems (e.g., Meropenem, Imipenem)
are stable against these hydrolytic enzymes due to their unique trans configuration (as
opposed to the cis configuration found in other beta-lactams), making them the drug of
choice for severe ESBL infections.
6. A patient with an ESBL-producing Klebsiella pneumoniae urinary tract infection is being
treated with Meropenem. The prescriber knows that carbapenems have the broadest
spectrum of activity among beta-lactams. What is the specific structural feature of
Meropenem that confers stability against beta-lactamases?
A. Its large molecular size prevents entry into the bacterial periplasm.
B. Its trans hydroxyethyl side chain protects the beta-lactam ring from hydrolysis.
C. Its lack of a beta-lactam ring makes it immune to hydrolysis.
D. Its high protein binding prevents enzyme interaction.
[CORRECT] B. Its trans hydroxyethyl side chain protects the beta-lactam ring from hydrolysis.
Rationale: Carbapenems possess a unique structure compared to penicillins and
cephalosporins, specifically a trans configuration of the hydroxyethyl side chain at position 6
of the beta-lactam ring. This structural difference sterically hinders beta-lactamases (including
ESBLs and AmpC) from accessing and hydrolyzing the beta-lactam ring, ensuring the drug
remains active.
NUR 521 Advanced Pharmacology EXAM 3
PRACTICE QUESTIONS AND ANSWERS WITH
RATIONALES 2025-2026 University of Alabama.
Domain 1: Antimicrobials, Beta-Lactams & Antivirals (14 Questions)
1. A 68-year-old male is admitted with bacteremia secondary to an infected diabetic foot
ulcer. Culture results confirm methicillin-resistant Staphylococcus aureus (MRSA). The
prescriber initiates Vancomycin. What is the specific mechanism of action that allows
Vancomycin to treat this resistant organism?
A. It inhibits the synthesis of the bacterial cell wall by binding to the 30S ribosomal subunit.
B. It binds to the D-alanyl-D-alanine terminal of the peptidoglycan precursor, preventing
cross-linking and transpeptidation.
C. It disrupts the cytoplasmic membrane potential, leading to rapid cell death.
D. It inhibits DNA gyrase, preventing bacterial DNA replication.
[CORRECT] B. It binds to the D-alanyl-D-alanine terminal of the peptidoglycan precursor,
preventing cross-linking and transpeptidation.
Rationale: Vancomycin is a glycopeptide antibiotic that exerts its bactericidal effect by binding
tightly to the D-alanyl-D-alanine terminus of the cell wall precursor pentapeptide. This
binding physically blocks the transglycosylation and transpeptidation (cross-linking) reactions
essential for cell wall rigidity. Unlike beta-lactams, which bind penicillin-binding proteins
(PBPs), Vancomycin binds the substrate itself, making it effective against MRSA strains that
have altered PBPs.
2. A patient with MRSA is being treated with Vancomycin. The nurse practitioner is
monitoring for nephrotoxicity. Which specific laboratory value must be monitored closely to
ensure safe therapeutic levels while minimizing toxicity?
A. Serum Prothrombin Time (PT)
, 2
B. Serum Creatinine and Vancomycin trough levels
C. Platelet count
D. Aspartate Aminotransferase (AST)
[CORRECT] B. Serum Creatinine and Vancomycin trough levels
Rationale: Vancomycin is associated with nephrotoxicity, particularly when trough levels are
consistently elevated (generally >15-20 mcg/mL). Monitoring serum creatinine allows for the
detection of acute renal injury, while monitoring random (or trough) levels ensures the drug
concentration is high enough to be effective (MIC ratio) but not so high as to cause kidney
damage.
3. A patient with a history of IV drug use presents with fever and a new heart murmur. Blood
cultures are pending, but there is a high clinical suspicion for MRSA endocarditis. The
prescriber orders Vancomycin. In addition to nephrotoxicity, what is another specific adverse
effect associated with the rapid infusion of Vancomycin?
A. Red Man Syndrome (histamine-mediated flushing and hypotension)
B. Stevens-Johnson Syndrome
C. Disulfiram-like reaction with alcohol
D. QT prolongation
[CORRECT] A. Red Man Syndrome (histamine-mediated flushing and hypotension)
Rationale: Red Man Syndrome is an infusion-related reaction characterized by flushing,
erythema, pruritus, and hypotension. It is caused by the direct, non-IgE-mediated release of
histamine from mast cells and basophils, typically occurring when Vancomycin is infused too
rapidly (e.g., over less than 60 minutes). It can be prevented or minimized by infusing the drug
over at least 60 to 120 minutes and pretreating with antihistamines.
, 3
4. Select all that apply: A patient is diagnosed with a severe MRSA infection. The healthcare
provider determines that Vancomycin therapy is appropriate. Which of the following are
critical monitoring parameters for this patient?
A. trough concentration drawn 30 minutes before the fourth dose
B. Serum creatinine and glomerular filtration rate (GFR)
C. Complete Blood Count (CBC) for eosinophilia
D. Ototoxicity assessment (hearing test)
E. Liver function tests (LFTs)
[CORRECT] A, B, C, D
Rationale:
A: Trough levels are drawn just before the next dose (steady state, usually prior to the 4th
dose) to ensure the minimum inhibitory concentration (MIC) is adequate.
B: Nephrotoxicity is a major risk, requiring renal function monitoring.
C: While less common than nephrotoxicity, Vancomycin can cause neutropenia or
eosinophilia.
D: Ototoxicity is a known, though less frequent, adverse effect of Vancomycin, particularly
with high trough levels or concurrent use of other ototoxic drugs (like aminoglycosides).
5. A 72-year-old female is admitted to the ICU with septic shock. Blood cultures grow
Escherichia coli that produces Extended-Spectrum Beta-Lactamase (ESBL). The initial empiric
therapy was Ceftriaxone. What is the specific pharmacologic rationale for de-escalating
therapy to a carbapenem (e.g., Meropenem)?
A. ESBL organisms hydrolyze the beta-lactam ring of penicillins and cephalosporins, rendering
them inactive.
B. ESBL organisms increase the efflux of Ceftriaxone out of the bacterial cell.
, 4
C. ESBL organisms alter the target binding site of Ceftriaxone.
D. Carbapenems are effective because they avoid the D-alanyl-D-alanine binding site.
[CORRECT] A. ESBL organisms hydrolyze the beta-lactam ring of penicillins and
cephalosporins, rendering them inactive.
Rationale: ESBLs are enzymes that confer resistance to penicillins, cephalosporins, and
aztreonam by hydrolyzing the beta-lactam ring. Carbapenems (e.g., Meropenem, Imipenem)
are stable against these hydrolytic enzymes due to their unique trans configuration (as
opposed to the cis configuration found in other beta-lactams), making them the drug of
choice for severe ESBL infections.
6. A patient with an ESBL-producing Klebsiella pneumoniae urinary tract infection is being
treated with Meropenem. The prescriber knows that carbapenems have the broadest
spectrum of activity among beta-lactams. What is the specific structural feature of
Meropenem that confers stability against beta-lactamases?
A. Its large molecular size prevents entry into the bacterial periplasm.
B. Its trans hydroxyethyl side chain protects the beta-lactam ring from hydrolysis.
C. Its lack of a beta-lactam ring makes it immune to hydrolysis.
D. Its high protein binding prevents enzyme interaction.
[CORRECT] B. Its trans hydroxyethyl side chain protects the beta-lactam ring from hydrolysis.
Rationale: Carbapenems possess a unique structure compared to penicillins and
cephalosporins, specifically a trans configuration of the hydroxyethyl side chain at position 6
of the beta-lactam ring. This structural difference sterically hinders beta-lactamases (including
ESBLs and AmpC) from accessing and hydrolyzing the beta-lactam ring, ensuring the drug
remains active.
